Reuters logo
BRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab Programs
December 7, 2017 / 12:15 PM / 5 days ago

BRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab Programs

Dec 7 (Reuters) - Aveo Pharmaceuticals Inc:

* AVEO ONCOLOGY ANNOUNCES CLINICAL UPDATES TO TIVOZANIB AND FICLATUZUMAB PROGRAMS

* AVEO PHARMACEUTICALS INC - FOR TIVOZANIB, ENROLLMENT COMPLETE IN PHASE 2 PORTION OF PHASE 1/2 TINIVO TRIAL IN ADVANCED RCC

* AVEO PHARMACEUTICALS INC - FOR FICLATUZUMAB, PHASE 2 STUDY OF FICLATUZUMAB IN COMBINATION WITH CETUXIMAB IN HNSCC INITIATED Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below